Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-845-579-5705

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

T: +1-347-918-3531

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Hypoventilation Management Market Snapshot (2023 to 2033)

The global hypoventilation management market is expected to reach a valuation of US$ 7.1 billion in 2023, and is projected to reach US$ 11.9 billion by 2033, trailing a CAGR of 5.3% during the forecast period.

Growing healthcare expenditure, advancement in the treatment options, unhealthy lifestyle, rising incidence of obesity, growing initiatives by government and private organisations to spread awareness towards health and lack of exercise in the daily routine are the factors that will expand hypoventilation syndrome treatment market.

Also, increase in the research and development activities and ongoing clinical trials will provide beneficial opportunities for hypoventilation syndrome treatment market in the forecast period of 2023-2033.

Report Attribute Details
Expected Market Value (2023) US$ 7.1 billion
Anticipated Forecast Value (2033) US$ 11.9 billion
Projected Growth Rate (2023 to 2033) CAGR 5.3%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Hypoventilation management Demand Analysis vs. Forecast 2023 to 2033

The market for hypoventilation management was worth US$ 6 billion in 2018, while growing at a CAGR of 3.42% during the historical period. The growth of hypoventilation drug market is being fuelled by increasing demand for medications to treat symptoms such as shortness of breath, coughing, mucus production, and wheezing, as well as the convenience and ease of using these treatments and therapies in the comfort of one's own home. A better understanding of respiratory illnesses, their treatments, and the necessary precautions has an additional effect on the market for medications used to treat hypoventilation diseases.

The value of the market for treatments for hypoventilation disease is boosted by the rising funding of research and development and drug production by governments and pharmaceutical corporations. Asthma and Chronic obstructive pulmonary diseases are on the rise, and the senior population is also on the rise, thus these are three main factors pushing the industry forward.

The global market value for Hypoventilation management is poised to increase significantly as a result of the government approving medicines and biosimilars. This market is booming thanks to improvements in healthcare infrastructure, shifting consumer preferences, and increasing disposable income. Considering the above-mentioned factors, the market of hypoventilation is expected to be worth US$ 11.9 billion with a CAGR of 5.3% by end of the forecast period.

Which are Some Prominent Drivers of the Hypoventilation management market?

Advancements in medical technology propelling market growth

Increasing prevalence of sleep related hypoventilation and growing healthcare expenditure are the major factors driving market growth. Furthermore, advancement in the medical technology, rising government funding and growing initiatives by public and private organisations to spread awareness about the disease and its preventive options are the factors that will expand hypoventilation treatment market.

Other factors including alcohol abuse, growing incidences of obesity, asthma and hypothyroidism and utilization of medication involving opiates and benzodiazepines will also help in propelling the market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

High cost of treatment restraining industry expansion

High cost of treatment and complications associated with various hypoventilation syndrome such as obesity related hypoventilation, sleep related hypoventilation, Chronic obstructive pulmonary disease, are the factors that will challenge market growth and will further restrain the hypoventilation syndrome treatment market in the forecast period.

Region-Wise Insights

What is the growth outlook in North America?

North America expected to dominate the market with the maximum share

North America accounted for the largest share of around 41% of the global market in 2022. The market in the region is projected to grow at a CAGR of 4.39% from 2023 to 2033. This can be ascribed to the highly structured healthcare industry and the availability of well-defined reimbursement policies from private and public health insurance firms.

Furthermore, growth in research & development activities to provide advanced and efficient products, and the presence of key players are driving the hypoventilation treatment market size in this region.

What is the growth prospect in South Asia?

The market in South-Asia expected to witness fastest CAGR

The market in South-Asia is expected to grow at the fastest CAGR of 5.5% during the forecast period. The region has a relatively untapped chronic obstructive pulmonary disease treatment market compared to developed regions.

Therefore, South Asia offers significant opportunities to market players. High prevalence of chronic obstructive pulmonary disease, increase in geriatric population, surge in patient population, and growth of the health care industry are propelling the hypoventilation treatment market in the region.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

By Disease Type, Which Segment will possess a Significant Share?

Chronic obstructive pulmonary disease driving growth with maximum share

Chronic obstructive pulmonary disease is projected to dominate the market with a market share of around 55% by end of the forecast period. This segment is estimated to reflect a CAGR of 6% during the forecast period. Adoption of combination therapies including LAMA-ICS, LABA-ICS, triple therapy, and other combination drugs are boosting the segment’s growth. Adoption of these therapies is increasing, as it is more effective than the separate use of bronchodilators and corticosteroids.

Growth in the number of patients successfully treated with combination therapy who were not showing signs of recovery with bronchodilators or corticosteroid treatments is anticipated to fuel the growth of chronic obstructive pulmonary disease treatment. Moreover, combination therapy is more effective than monotherapy for improving symptoms and quality of life. Thus, boosting the segment’s growth.

By end-user, which segment will possess market hegemony

Hospitals will lead the segment with the maximum share

This segment is expected to lead the market with a market share of 71% by end of the forecast period. Rising investments in healthcare infrastructure, easy availability of diagnostic machines, and easy access to skilled professionals are some of the factors driving the growth of this segment. Furthermore, hospitals are convenient for using combination therapies in the treatment of hypoventilation disorder which also boosts this segment’s growth.

Start-ups in the Hypoventilation management market

  • Founded in 2016, US Sleep Apnea is an Oakland, United States-based start-up that offers wearable devices for sleep management. The company provides a home-based diagnostic device based on online consultation with sleep experts. The device enables patients to monitor the factors associated with sleep apnea. It monitors sleep-related symptoms such as breathing patterns, oxygen levels, and heart rate. The diagnostic results can be interpreted in the lab and shared with the patients.
  • Founded in 2006, Circassia Pharmaceuticals is an Oxford, United Kingdom-based company. It is focused on developing devices for treatment of allergy and respiratory disease. The company has developed NIOX for asthma management and Tudorza to treat chronic obstructive pulmonary disease. The next-generation immunotherapy technology is in phase III testing for cat allergy and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed, and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia has also developed Flixotide/Flovent substitute and Seretide/Advair substitute. The Company is also developing a number of COPD of treatments, Duaklir US, Spiriva substitute, LABA/LAMA formulation and COPD therapy formulation. It was granted funding of USD 157 million from Richard Griffiths, Invesco Perpetual, Imperial Innovations and 2 others.

Market Competition

The global Hypoventilation management market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition. The major players in the market are: Accord Healthcare Limited, Avet Pharmaceuticals Inc, Nostrum Laboratories Inc, Lannett Co Inc, Strides Pharma Science Limited, X Gen Pharmaceuticals Inc, ResMed, Koninklijke Philips NV, Hikma Pharmaceuticals, Lincare Holdings

Some recent developments in this industry are:

  • In June 2022, Verona Pharma, a pharmaceutical company, announced the completion of the patient enrolment, with more than 800 subjects involved for its randomized ENHANCE-1 trial. The study will evaluate ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease, a type of hypoventilation disorder. It is a critical step for the phase III ENHANCE trial with top-line data expected by the end of the year 2022 and further data from ENHANCE-2 in the third quarter of 2022.
  • In November 2021, AstraZeneca announced that it had sold rights to sell Tudorza, also known as Eklira abroad, and Duaklir to the Switzerland-based pharmaceutical company Covis Pharma Group for US$ 270 Million. These products are indicated for the treatment of various types of hypoventilation disorders.
  • In May 2022, Alembic Pharmaceuticals Ltd, a pharmaceutical company, received final approval from the USA health regulator for its generic version of Arformoterol Tartrate inhalation solution indicated for long-term treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. The approval by the USA Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution is for strength of 15 mcg (base)/2 mL unit-dose vial.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 7.1 billion
Market Value in 2033 US$ 11.9 billion
Growth Rate CAGR of 5.3% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Disease Type
  • Treatment
  • End User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • UAE
  • South Africa
  • Israel
Key Companies Profiled
  • Accord Healthcare Limited
  • Avet Pharmaceuticals Inc.
  • Nostrum Laboratories Inc.
  • Lannett Co Inc.
  • Strides Pharma Science Limited
  • X Gen Pharmaceuticals Inc.
  • ResMed
  • Koninklijke Philips NV
  • Hikma Pharmaceuticals
  • Lincare Holdings
Customization Available Upon Request

Key Segments Profiled in the Hypoventilation Management Market Industry

By Disease Type:

  • Chronic Obstructive Pulmonary Disease
  • Obesity Hypoventilation Syndrome (OHS)
  • Central Alveolar Hypoventilation
  • Neuromuscular Disorders

By Treatment Type:

  • Oxygen Therapy
  • Non-Invasive Mechanical Ventilation
  • Drug Therapy

By End User:

  • Hospitals
  • Specialty clinics
  • Home care

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa

Frequently Asked Questions

What is the anticipated growth of the Hypoventilation management market until 2033?

FMI projects the global Hypoventilation management market to expand at a 5.3% value CAGR by 2033.

What is the estimated market value of the Hypoventilation management market expected in 2033?

The global Hypoventilation management market is expected to garner a market value of US$ 11.9 billion by 2033.

Which region is forecast to be the most lucrative for Hypoventilation management market growth?

FMI has projected North America to be one of the most lucrative regions for Hypoventilation management market.

Which region is expected to grow fastest during the forecast period?

South Asia region is anticipated to grow fastest during the forecast period.

Table of Content

1. Executive Summary | Hypoventilation Management Market

        1.1. Global Market Outlook

        1.2. Demand-side Trends

        1.3. Supply-side Trends

        1.4. Technology Roadmap Analysis

        1.5. Analysis and Recommendations

2. Market Overview

        2.1. Market Coverage / Taxonomy

        2.2. Market Definition / Scope / Limitations

3. Market Background

        3.1. Market Dynamics

            3.1.1. Drivers

            3.1.2. Restraints

            3.1.3. Opportunity

            3.1.4. Trends

        3.2. Scenario Forecast

            3.2.1. Demand in Optimistic Scenario

            3.2.2. Demand in Likely Scenario

            3.2.3. Demand in Conservative Scenario

        3.3. Opportunity Map Analysis

        3.4. Investment Feasibility Matrix

        3.5. PESTLE and Porter’s Analysis

        3.6. Regulatory Landscape

            3.6.1. By Key Regions

            3.6.2. By Key Countries

        3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

        4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

        4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

            4.2.1. Y-o-Y Growth Trend Analysis

            4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type

        5.1. Introduction / Key Findings

        5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022

        5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033

            5.3.1. Chronic Obstructive Pulmonary Disease

            5.3.2. Obesity Hypoventilation Syndrome (OHS)

            5.3.3. Central Alveolar Hypoventilation

            5.3.4. Neuromuscular Disorders

        5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022

        5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

        6.1. Introduction / Key Findings

        6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

        6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

            6.3.1. Oxygen Therapy

            6.3.2. Non-invasive Mechanical Ventilation

            6.3.3. Drug Therapy

        6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

        6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

        7.1. Introduction / Key Findings

        7.2. Historical Market Size Value (US$ Million) Analysis By End Users , 2018 to 2022

        7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users , 2023 to 2033

            7.3.1. Hospitals

            7.3.2. Specialty Clinics

            7.3.3. Home Care

        7.4. Y-o-Y Growth Trend Analysis By End Users , 2018 to 2022

        7.5. Absolute $ Opportunity Analysis By End Users , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

        8.1. Introduction

        8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

        8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

            8.3.1. North America

            8.3.2. Latin America

            8.3.3. Europe

            8.3.4. South Asia

            8.3.5. East Asia

            8.3.6. Oceania

            8.3.7. MIDDLE EAST AND AFRICA

        8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            9.2.1. By Country

                9.2.1.1. USA

                9.2.1.2. Canada

            9.2.2. By Disease Type

            9.2.3. By Treatment

            9.2.4. By End Users

        9.3. Market Attractiveness Analysis

            9.3.1. By Country

            9.3.2. By Disease Type

            9.3.3. By Treatment

            9.3.4. By End Users

        9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            10.2.1. By Country

                10.2.1.1. Brazil

                10.2.1.2. Mexico

                10.2.1.3. Rest of Latin America

            10.2.2. By Disease Type

            10.2.3. By Treatment

            10.2.4. By End Users

        10.3. Market Attractiveness Analysis

            10.3.1. By Country

            10.3.2. By Disease Type

            10.3.3. By Treatment

            10.3.4. By End Users

        10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            11.2.1. By Country

                11.2.1.1. Germany

                11.2.1.2. United kingdom

                11.2.1.3. France

                11.2.1.4. Spain

                11.2.1.5. Italy

                11.2.1.6. Rest of Europe

            11.2.2. By Disease Type

            11.2.3. By Treatment

            11.2.4. By End Users

        11.3. Market Attractiveness Analysis

            11.3.1. By Country

            11.3.2. By Disease Type

            11.3.3. By Treatment

            11.3.4. By End Users

        11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            12.2.1. By Country

                12.2.1.1. India

                12.2.1.2. Malaysia

                12.2.1.3. Singapore

                12.2.1.4. Thailand

                12.2.1.5. Rest of South Asia

            12.2.2. By Disease Type

            12.2.3. By Treatment

            12.2.4. By End Users

        12.3. Market Attractiveness Analysis

            12.3.1. By Country

            12.3.2. By Disease Type

            12.3.3. By Treatment

            12.3.4. By End Users

        12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            13.2.1. By Country

                13.2.1.1. China

                13.2.1.2. Japan

                13.2.1.3. South Korea

            13.2.2. By Disease Type

            13.2.3. By Treatment

            13.2.4. By End Users

        13.3. Market Attractiveness Analysis

            13.3.1. By Country

            13.3.2. By Disease Type

            13.3.3. By Treatment

            13.3.4. By End Users

        13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            14.2.1. By Country

                14.2.1.1. Australia

                14.2.1.2. New Zealand

            14.2.2. By Disease Type

            14.2.3. By Treatment

            14.2.4. By End Users

        14.3. Market Attractiveness Analysis

            14.3.1. By Country

            14.3.2. By Disease Type

            14.3.3. By Treatment

            14.3.4. By End Users

        14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

        15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

        15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

            15.2.1. By Country

                15.2.1.1. GCC Countries

                15.2.1.2. South Africa

                15.2.1.3. Israel

                15.2.1.4. Rest of Middle East and Africa

            15.2.2. By Disease Type

            15.2.3. By Treatment

            15.2.4. By End Users

        15.3. Market Attractiveness Analysis

            15.3.1. By Country

            15.3.2. By Disease Type

            15.3.3. By Treatment

            15.3.4. By End Users

        15.4. Key Takeaways

16. Key Countries Market Analysis

        16.1. USA

            16.1.1. Pricing Analysis

            16.1.2. Market Share Analysis, 2022

                16.1.2.1. By Disease Type

                16.1.2.2. By Treatment

                16.1.2.3. By End Users

        16.2. Canada

            16.2.1. Pricing Analysis

            16.2.2. Market Share Analysis, 2022

                16.2.2.1. By Disease Type

                16.2.2.2. By Treatment

                16.2.2.3. By End Users

        16.3. Brazil

            16.3.1. Pricing Analysis

            16.3.2. Market Share Analysis, 2022

                16.3.2.1. By Disease Type

                16.3.2.2. By Treatment

                16.3.2.3. By End Users

        16.4. Mexico

            16.4.1. Pricing Analysis

            16.4.2. Market Share Analysis, 2022

                16.4.2.1. By Disease Type

                16.4.2.2. By Treatment

                16.4.2.3. By End Users

        16.5. Germany

            16.5.1. Pricing Analysis

            16.5.2. Market Share Analysis, 2022

                16.5.2.1. By Disease Type

                16.5.2.2. By Treatment

                16.5.2.3. By End Users

        16.6. United Kingdom

            16.6.1. Pricing Analysis

            16.6.2. Market Share Analysis, 2022

                16.6.2.1. By Disease Type

                16.6.2.2. By Treatment

                16.6.2.3. By End Users

        16.7. France

            16.7.1. Pricing Analysis

            16.7.2. Market Share Analysis, 2022

                16.7.2.1. By Disease Type

                16.7.2.2. By Treatment

                16.7.2.3. By End Users

        16.8. Spain

            16.8.1. Pricing Analysis

            16.8.2. Market Share Analysis, 2022

                16.8.2.1. By Disease Type

                16.8.2.2. By Treatment

                16.8.2.3. By End Users

        16.9. Italy

            16.9.1. Pricing Analysis

            16.9.2. Market Share Analysis, 2022

                16.9.2.1. By Disease Type

                16.9.2.2. By Treatment

                16.9.2.3. By End Users

        16.10. India

            16.10.1. Pricing Analysis

            16.10.2. Market Share Analysis, 2022

                16.10.2.1. By Disease Type

                16.10.2.2. By Treatment

                16.10.2.3. By End Users

        16.11. Malaysia

            16.11.1. Pricing Analysis

            16.11.2. Market Share Analysis, 2022

                16.11.2.1. By Disease Type

                16.11.2.2. By Treatment

                16.11.2.3. By End Users

        16.12. Singapore

            16.12.1. Pricing Analysis

            16.12.2. Market Share Analysis, 2022

                16.12.2.1. By Disease Type

                16.12.2.2. By Treatment

                16.12.2.3. By End Users

        16.13. Thailand

            16.13.1. Pricing Analysis

            16.13.2. Market Share Analysis, 2022

                16.13.2.1. By Disease Type

                16.13.2.2. By Treatment

                16.13.2.3. By End Users

        16.14. China

            16.14.1. Pricing Analysis

            16.14.2. Market Share Analysis, 2022

                16.14.2.1. By Disease Type

                16.14.2.2. By Treatment

                16.14.2.3. By End Users

        16.15. Japan

            16.15.1. Pricing Analysis

            16.15.2. Market Share Analysis, 2022

                16.15.2.1. By Disease Type

                16.15.2.2. By Treatment

                16.15.2.3. By End Users

        16.16. South Korea

            16.16.1. Pricing Analysis

            16.16.2. Market Share Analysis, 2022

                16.16.2.1. By Disease Type

                16.16.2.2. By Treatment

                16.16.2.3. By End Users

        16.17. Australia

            16.17.1. Pricing Analysis

            16.17.2. Market Share Analysis, 2022

                16.17.2.1. By Disease Type

                16.17.2.2. By Treatment

                16.17.2.3. By End Users

        16.18. New Zealand

            16.18.1. Pricing Analysis

            16.18.2. Market Share Analysis, 2022

                16.18.2.1. By Disease Type

                16.18.2.2. By Treatment

                16.18.2.3. By End Users

        16.19. GCC Countries

            16.19.1. Pricing Analysis

            16.19.2. Market Share Analysis, 2022

                16.19.2.1. By Disease Type

                16.19.2.2. By Treatment

                16.19.2.3. By End Users

        16.20. South Africa

            16.20.1. Pricing Analysis

            16.20.2. Market Share Analysis, 2022

                16.20.2.1. By Disease Type

                16.20.2.2. By Treatment

                16.20.2.3. By End Users

        16.21. Israel

            16.21.1. Pricing Analysis

            16.21.2. Market Share Analysis, 2022

                16.21.2.1. By Disease Type

                16.21.2.2. By Treatment

                16.21.2.3. By End Users

17. Market Structure Analysis

        17.1. Competition Dashboard

        17.2. Competition Benchmarking

        17.3. Market Share Analysis of Top Players

            17.3.1. By Regional

            17.3.2. By Disease Type

            17.3.3. By Treatment

            17.3.4. By End Users

18. Competition Analysis

        18.1. Competition Deep Dive

            18.1.1. Accord Healthcare Limited

                18.1.1.1. Overview

                18.1.1.2. Product Portfolio

                18.1.1.3. Profitability by Market Segments

                18.1.1.4. Sales Footprint

                18.1.1.5. Strategy Overview

                    18.1.1.5.1. Marketing Strategy

            18.1.2. Avet Pharmaceuticals Inc

                18.1.2.1. Overview

                18.1.2.2. Product Portfolio

                18.1.2.3. Profitability by Market Segments

                18.1.2.4. Sales Footprint

                18.1.2.5. Strategy Overview

                    18.1.2.5.1. Marketing Strategy

            18.1.3. Nostrum Laboratories Inc

                18.1.3.1. Overview

                18.1.3.2. Product Portfolio

                18.1.3.3. Profitability by Market Segments

                18.1.3.4. Sales Footprint

                18.1.3.5. Strategy Overview

                    18.1.3.5.1. Marketing Strategy

            18.1.4. Lannett Co Inc

                18.1.4.1. Overview

                18.1.4.2. Product Portfolio

                18.1.4.3. Profitability by Market Segments

                18.1.4.4. Sales Footprint

                18.1.4.5. Strategy Overview

                    18.1.4.5.1. Marketing Strategy

            18.1.5. Strides Pharma Science Limited

                18.1.5.1. Overview

                18.1.5.2. Product Portfolio

                18.1.5.3. Profitability by Market Segments

                18.1.5.4. Sales Footprint

                18.1.5.5. Strategy Overview

                    18.1.5.5.1. Marketing Strategy

            18.1.6. X Gen Pharmaceuticals Inc

                18.1.6.1. Overview

                18.1.6.2. Product Portfolio

                18.1.6.3. Profitability by Market Segments

                18.1.6.4. Sales Footprint

                18.1.6.5. Strategy Overview

                    18.1.6.5.1. Marketing Strategy

            18.1.7. ResMed

                18.1.7.1. Overview

                18.1.7.2. Product Portfolio

                18.1.7.3. Profitability by Market Segments

                18.1.7.4. Sales Footprint

                18.1.7.5. Strategy Overview

                    18.1.7.5.1. Marketing Strategy

            18.1.8. Koninklijke Philips NV

                18.1.8.1. Overview

                18.1.8.2. Product Portfolio

                18.1.8.3. Profitability by Market Segments

                18.1.8.4. Sales Footprint

                18.1.8.5. Strategy Overview

                    18.1.8.5.1. Marketing Strategy

            18.1.9. Hikma Pharmaceuticals

                18.1.9.1. Overview

                18.1.9.2. Product Portfolio

                18.1.9.3. Profitability by Market Segments

                18.1.9.4. Sales Footprint

                18.1.9.5. Strategy Overview

                    18.1.9.5.1. Marketing Strategy

            18.1.10. Lincare Holdings

                18.1.10.1. Overview

                18.1.10.2. Product Portfolio

                18.1.10.3. Profitability by Market Segments

                18.1.10.4. Sales Footprint

                18.1.10.5. Strategy Overview

                    18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 4: Global Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 7: North America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 8: North America Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 10: Latin America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 11: Latin America Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 12: Latin America Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 15: Europe Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 16: Europe Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 18: South Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 19: South Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 20: South Asia Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 22: East Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 23: East Asia Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 24: East Asia Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 26: Oceania Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 27: Oceania Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 28: Oceania Market Value (US$ Million) Forecast by End Users , 2018 to 2033

Table 29: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 30: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033

Table 31: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Treatment, 2018 to 2033

Table 32: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by End Users , 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by End Users, 2023 to 2033

Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 8: Global Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 11: Global Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 14: Global Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 15: Global Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 17: Global Market Attractiveness by Disease Type, 2023 to 2033

Figure 18: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 19: Global Market Attractiveness by End Users , 2023 to 2033

Figure 20: Global Market Attractiveness by Region, 2023 to 2033

Figure 21: North America Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 22: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 23: North America Market Value (US$ Million) by End Users , 2023 to 2033

Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 28: North America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 31: North America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 34: North America Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 35: North America Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 37: North America Market Attractiveness by Disease Type, 2023 to 2033

Figure 38: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 39: North America Market Attractiveness by End Users , 2023 to 2033

Figure 40: North America Market Attractiveness by Country, 2023 to 2033

Figure 41: Latin America Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 42: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 43: Latin America Market Value (US$ Million) by End Users , 2023 to 2033

Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 51: Latin America Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 54: Latin America Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 57: Latin America Market Attractiveness by Disease Type, 2023 to 2033

Figure 58: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Latin America Market Attractiveness by End Users , 2023 to 2033

Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 61: Europe Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 62: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 63: Europe Market Value (US$ Million) by End Users , 2023 to 2033

Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 68: Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 71: Europe Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 74: Europe Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 77: Europe Market Attractiveness by Disease Type, 2023 to 2033

Figure 78: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 79: Europe Market Attractiveness by End Users , 2023 to 2033

Figure 80: Europe Market Attractiveness by Country, 2023 to 2033

Figure 81: South Asia Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 82: South Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 83: South Asia Market Value (US$ Million) by End Users , 2023 to 2033

Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 88: South Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 89: South Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 91: South Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 92: South Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 94: South Asia Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 95: South Asia Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 96: South Asia Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 97: South Asia Market Attractiveness by Disease Type, 2023 to 2033

Figure 98: South Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 99: South Asia Market Attractiveness by End Users , 2023 to 2033

Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 101: East Asia Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 102: East Asia Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 103: East Asia Market Value (US$ Million) by End Users , 2023 to 2033

Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 108: East Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 109: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 111: East Asia Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 112: East Asia Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 114: East Asia Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 115: East Asia Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 116: East Asia Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 117: East Asia Market Attractiveness by Disease Type, 2023 to 2033

Figure 118: East Asia Market Attractiveness by Treatment, 2023 to 2033

Figure 119: East Asia Market Attractiveness by End Users , 2023 to 2033

Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 121: Oceania Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 122: Oceania Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 123: Oceania Market Value (US$ Million) by End Users , 2023 to 2033

Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 128: Oceania Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 129: Oceania Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 131: Oceania Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 132: Oceania Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 134: Oceania Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 135: Oceania Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 136: Oceania Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 137: Oceania Market Attractiveness by Disease Type, 2023 to 2033

Figure 138: Oceania Market Attractiveness by Treatment, 2023 to 2033

Figure 139: Oceania Market Attractiveness by End Users , 2023 to 2033

Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 141: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Disease Type, 2023 to 2033

Figure 142: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 143: MIDDLE EAST AND AFRICA Market Value (US$ Million) by End Users , 2023 to 2033

Figure 144: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033

Figure 145: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 146: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 147: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 148: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033

Figure 149: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033

Figure 150: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033

Figure 151: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Treatment, 2018 to 2033

Figure 152: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 153: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 154: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by End Users , 2018 to 2033

Figure 155: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by End Users , 2023 to 2033

Figure 156: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by End Users , 2023 to 2033

Figure 157: MIDDLE EAST AND AFRICA Market Attractiveness by Disease Type, 2023 to 2033

Figure 158: MIDDLE EAST AND AFRICA Market Attractiveness by Treatment, 2023 to 2033

Figure 159: MIDDLE EAST AND AFRICA Market Attractiveness by End Users , 2023 to 2033

Figure 160: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033

Recommendations

Healthcare

COPD Therapeutics Market

Published : August 2023

Healthcare

Chronic Obstructive Pulmonary Disease (COPD) Market

Published : December 2022

Explore Healthcare Insights

View Reports

Hypoventilation Management Market